Steroids · 2025
Are dexamethasone implants a safe and effective breakthrough in uveitis treatment? A systematic review and meta-analysis.
СтатьяСистематический обзорМетаанализНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Chen Kai-Yang, Chan Hoi-Chun, Chan Chi-Ming
Аннотация
BACKGROUND: Uveitis encompasses inflammatory conditions affecting the iris, ciliary body, and choroid. Its management relied on corticosteroids, immunosuppressive agents, and, more recently, biologic therapies. The development of sustained-release intravitreal corticosteroid delivery systems, like dexamethasone intravitreal implants, has revolutionized the treatment of posterior uveitis.
OBJECTIVES: To critically appraise the evidence of the safety and efficacy of dexamethasone implants in managing Uveitis.
METHODS: A systematic review of the safety and efficacy of dexamethasone implants in managing Uveitis was conducted. A comprehensive and systematic electronic database search was conducted in Scopus, PubMed, Cochrane Library, ScienceDirect, Google Scholar, and Wiley Online Library for studies published from their inception to the present date. Modified PICOS criteria were used to screen and select the eligible studies from the potential articles retrieved from the database search. Studies were considered if they included patients with uveitis. A comprehensive risk of bias assessment was conducted using the Newcastle Ottawa Scale (NOS) for cohort studies, the Risk of Bias in Non-Randomized Studies (ROBINS-I) tool for non-randomized trials, the risk of bias visualization tool (ROB 2.0) tool for RCTs, and the National Institutes of Health (NIH) quality assessment tool for Interventional case-series. Data were then procedurally extracted and analyzed.
RESULTS: The study selection process identified 29 studies, including 1,086 eyes. Dexamethasone implant significantly reduced central retinal/macular thickness at all time points: 150.4 μm at 1 month (p < 0.001), 200.8 μm at 3 months (p < 0.001), and 225.5 μm at 6-24 months (p < 0.001). Inflammation control was achieved in 80.8 % of cases (p < 0.001). Visual acuity improvements were modest at 6 months (p = 0.078) but significant long-term (p < 0.001). However, the dexamethasone implant resulted in cataract formation (p = 0.010), with a recurrence rate of 0.501 (p = 0.968).
CONCLUSION: Dexamethasone implants offer clinically significant benefits, resulting in substantial reductions in central retinal thickness, improvements in visual acuity, and effective control of inflammation in patients with uveitis.
OBJECTIVES: To critically appraise the evidence of the safety and efficacy of dexamethasone implants in managing Uveitis.
METHODS: A systematic review of the safety and efficacy of dexamethasone implants in managing Uveitis was conducted. A comprehensive and systematic electronic database search was conducted in Scopus, PubMed, Cochrane Library, ScienceDirect, Google Scholar, and Wiley Online Library for studies published from their inception to the present date. Modified PICOS criteria were used to screen and select the eligible studies from the potential articles retrieved from the database search. Studies were considered if they included patients with uveitis. A comprehensive risk of bias assessment was conducted using the Newcastle Ottawa Scale (NOS) for cohort studies, the Risk of Bias in Non-Randomized Studies (ROBINS-I) tool for non-randomized trials, the risk of bias visualization tool (ROB 2.0) tool for RCTs, and the National Institutes of Health (NIH) quality assessment tool for Interventional case-series. Data were then procedurally extracted and analyzed.
RESULTS: The study selection process identified 29 studies, including 1,086 eyes. Dexamethasone implant significantly reduced central retinal/macular thickness at all time points: 150.4 μm at 1 month (p < 0.001), 200.8 μm at 3 months (p < 0.001), and 225.5 μm at 6-24 months (p < 0.001). Inflammation control was achieved in 80.8 % of cases (p < 0.001). Visual acuity improvements were modest at 6 months (p = 0.078) but significant long-term (p < 0.001). However, the dexamethasone implant resulted in cataract formation (p = 0.010), with a recurrence rate of 0.501 (p = 0.968).
CONCLUSION: Dexamethasone implants offer clinically significant benefits, resulting in substantial reductions in central retinal thickness, improvements in visual acuity, and effective control of inflammation in patients with uveitis.